Published online Nov 27, 2026. doi: 10.4254/wjh.126504
Revised: August 28, 2026
Accepted: November 9, 2026
Published online: November 27, 2026
Processing time: 105 Days and 5.5 Hours
Clinically significant portal hypertension (CSPH) is traditionally associated with advanced liver fibrosis, but its occurrence and predictors in histologically early stage primary biliary cholangitis (PBC) remain unclear.
To identify clinical features and independent risk factors for CSPH in patients with biopsy proven early stage (Scheuer stage I–II) PBC, facilitating early re
This retrospective study enrolled 110 patients with histologically early-stage PBC at Beijing Ditan Hospital (2020-2023). Patients were divided into CSPH (n = 27) and non CSPH (n = 83) groups based on Baveno VII criteria. Demographic, la
Both groups were predominantly middle-aged women. The CSPH group had significantly lower white blood cell count, hemoglobin, platelet, albumin, cholinesterase, and low-density lipoprotein cholesterol levels, and higher total bilirubin, alkaline phosphatase, and total bile acid levels (all P < 0.05). Drug allergy history (29.6% vs 8.4%, P < 0.05) and histological stage II (63.0% vs 39.8%, P < 0.05) were more frequent in the CSPH group. Autoantibody profiles (anti-mitochondrial antibodies, antinuclear antibody, anti-centromere, anti-sp100, anti-gp210) and immunoglobulin levels did not differ between groups. Imaging showed larger portal vein diameter and higher liver stiffness in the CSPH group (both P < 0.05). Multivariate analysis identified drug allergies [odds ratio (OR) = 5.948, 95%CI: 1.494-23.675, P = 0.011] and main portal vein diameter (OR = 2.563, 95%CI: 1.635-4.017, P < 0.001) as independent factors associated with CSPH.
CSPH is not rare in histologically early-stage PBC, especially at stage II, and is accompanied by worse liver function and cytopenias. Drug allergy history and increased portal vein diameter are independently associated with CSPH, whereas common autoantibodies appear unrelated. These findings may help stratify early-stage PBC patients at risk of CSPH, though prospective validation is warranted.
Core Tip: In early-stage primary biliary cholangitis, pre-cirrhotic clinically significant portal hypertension was common (24.5%). Drug-allergy history and wider main portal vein were independent risk factors, suggesting simple clues for risk stratification. However, the single-center retrospective design, modest sample, lack of hepatic venous pressure gradient (HVPG) confirmation, and short follow-up limit causal and prognostic inference. Routine care should include allergy history and ultrasound portal-vein monitoring; multicenter prospective HVPG-based studies are needed to validate pre